Top Markets
Coin of the day
Notable Labs, Ltd. Notable Labs, Ltd.

Notable Labs, Ltd.

NTBL
株式のランク #41089
Notable Labs, Ltd. operates as a clinical-stage therapeutic platform company,... Notable Labs, Ltd. operates as a clinical-stage therapeutic platform company, concentrating on creating predictive, personalized treatments for individuals battling cancer. Through its proprietary Predictive Precision Medicines Platform (PPMP), the company virtually tests potential cancer therapies to forecast an individual patient's likely response to a specific drug. The primary goal of the PPMP is to identify and qualify patients who are expected to respond favorably before they even begin treatment, thereby significantly accelerating the clinical development process for these specific patient groups. Notable Labs' current development pipeline includes Volasertib, a potent Polo-like kinase 1 (PLK-1) inhibitor designed to treat acute myeloid leukemia (AML), pediatric leukemia, and myelodysplastic syndromes. Additionally, it features Fosciclopirox, a prodrug of ciclopirox, also aimed at acute myeloid leukemia. The company's headquarters are located in Foster City, California.
株価
$0.0202
最終同期: 2024-11-19
時価総額
$44.67K
変化(1日)
-0.49%
変化(1年)
0.00%
IL
取引 Notable Labs, Ltd. (NTBL)

カテゴリー

Notable Labs, Ltd.(NTBL)の営業利益率
August 2026 時点の営業利益率 TTM: -4,728.06%
Notable Labs, Ltd. の最新の財務報告と株価によると、現在の営業利益率(TTM)は -4,728.06% です。2022 年末時点では -161,550.00% でした。
Notable Labs, Ltd. の営業利益率の履歴(2015 から 2026)
各年末の営業利益率
営業利益率 変化
2026 (TTM) -4,728.06% 0.00%
2023 -4,728.06% -97.07%
2022 -161,550.00% 2,622.11%
2021 -5,934.74% 123.50%
2020 -2,655.42% -25.69%
2019 -3,573.31% -9.98%
2018 -3,969.57% 4,184.94%
2017 -92.64% 0.00%
2016 0.00% 0.00%
2015 0.00% 0.00%
同業他社の営業利益率
企業 営業利益率 営業利益率の差
38.97% -100.01%
US
28.81% -100.01%
NL
0.00% -
CH
0.00% -
KR
31.23% -100.01%
BE
企業の営業利益率とは?
営業利益率は、企業の収益性を評価するための重要な指標です。高い営業利益率は一般的に良いとされており、企業が製品やサービスをその生産コストよりもはるかに高く販売できていることを示します。営業利益率は、企業の利益を売上高で割ることで計算されます。